Neuphoria Therapeutics Ratios (2020-2025) | NEUP

Ratios Jun2020 Dec2021 Jun2022 Jun2023 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin -291.49%74.54%116,256.64%
EBIT Margin -558.84%79.85%43,981.65%
EBITDA Margin 487.66%73.78%58,915.04%
Operating Margin -558.84%79.85%43,981.65%
Net Margin -289.74%75.08%114,247.12%
FCF Margin -506.72%76.61%27,135.00%
Efficiency
Assets Average 25.07M48.10M37.76M25.83M20.54M24.44M29.65M27.97M31.97M
Equity Average 26.11M42.34M31.46M19.61M15.41M19.87M22.50M15.76M21.11M
Invested Capital 8.31M43.92M40.76M22.15M17.07M13.75M26.00M19.00M12.51M29.70M
Asset Utilization Ratio -0.010.030.640.530.560.47
Leverage & Solvency
Equity Ratio 11.610.890.870.770.740.760.850.660.460.81
Valuation
Enterprise Value -3.00M-29.40M-24.04M-12.20M-8.08M-4.42M-17.04M-14.29M-13.73M-22.25M
Return Ratios
Return on Sales -2.90%0.75%1,142.47%-1.00%-0.80%
Return on Capital Employed -0.04%-0.14%-0.12%
Return on Invested Capital -0.05%-0.20%-0.16%
Return on Assets -0.03%-0.13%0.35%-0.22%-0.56%-0.38%
Return on Equity -0.04%-0.18%0.43%-0.29%-1.00%-0.57%